Study: Lesion differences can determine MS treatment benefits

08/12/2005 | Yahoo!

Researchers have identified key distinctions in multiple sclerosis lesions that can indicate whether patients can benefit from a therapy called plasma exchange. Only those patients whose lesions include evidence of antibody deposition or immune cell activity called "complement activation" are likely to respond to the plasma exchange treatment for acute attacks, according to the study.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI